Related Experiment Video

Updated: Jun 25, 2026

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography
09:34

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Published on: February 17, 2022

3.3K

A pediatric case of KMT2A-rearranged B-lymphoblastic lymphoma treated with high-risk therapy

Lindsey Murphy1, Bradford Siegele2, Billie Carstens3

  • 1Department of Pediatrics, City of Hope Comprehensive Cancer Center, Duarte, CA, USA.

Leukemia & Lymphoma
|February 19, 2024
PubMed
Abstract

No abstract available in PubMed .

More Related Videos

Assessment of Chimeric Antigen Receptor T Cell-Associated Toxicities Using an Acute Lymphoblastic Leukemia Patient-Derived Xenograft Mouse Model
06:08

Assessment of Chimeric Antigen Receptor T Cell-Associated Toxicities Using an Acute Lymphoblastic Leukemia Patient-Derived Xenograft Mouse Model

Published on: February 10, 2023

1.3K
A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy
09:56

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

Published on: February 21, 2025

519

Related Experiment Videos

Last Updated: Jun 25, 2026

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography
09:34

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Published on: February 17, 2022

3.3K
Assessment of Chimeric Antigen Receptor T Cell-Associated Toxicities Using an Acute Lymphoblastic Leukemia Patient-Derived Xenograft Mouse Model
06:08

Assessment of Chimeric Antigen Receptor T Cell-Associated Toxicities Using an Acute Lymphoblastic Leukemia Patient-Derived Xenograft Mouse Model

Published on: February 10, 2023

1.3K
A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy
09:56

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

Published on: February 21, 2025

519

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...

Articles linked to this work by shared authors, journal, and citation graph.

A Rare Finding of Mosaic 45,XX,der(13;21)(q10;q10)[15]/46,XX,r(13)(p11.2q33) Following Abnormal Prenatal Chromosomal Microarray Testing.

Case reports in genetics·2026

Splenosis of the liver: a unique clinicopathologic challenge.

Journal of hematopathology·2026

Recurrent SWI/SNF Deficiency Defines a Subset of Peripheral T-Cell Lymphoma With Distinct Clinicopathologic Features.

Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc·2026

Squamous papilloma of the oral cavity and oropharynx in children.

International journal of pediatric otorhinolaryngology·2025

The integration of blinatumomab consolidation in the CALGB 10403 regimen for adults with B-cell precursor acute lymphoblastic leukaemia in measurable residual disease-negative remission.

British journal of haematology·2025

Universal Premedication Does Not Impact Transition to Short-acting Asparaginase or Incidence of Hypersensitivity to Pegylated Asparaginase: A Single-institution Experience.

Journal of pediatric hematology/oncology·2025

Venetoclax consolidation deepens response and enables measurable residual disease-guided finite therapy in BTK inhibitor-treated chronic lymphocytic leukemia.

Leukemia & lymphoma·2026

Clinical outcomes of adults with PAX5-mutated or rearranged B-cell acute lymphoblastic leukemia.

Leukemia & lymphoma·2026

Efficacy and safety of three-drug induction-based MASPORE 2003 chemotherapy protocol in standard- and intermediate-risk pediatric acute lymphoblastic leukemia: a decade-long single-center experience from India.

Leukemia & lymphoma·2026

Characterizing the landscape of hospitalizations for multiple myeloma in Spain: a retrospective analysis (2016-2023).

Leukemia & lymphoma·2026

Diagnostic accuracy and clinical usefulness of lung ultrasound in onco hematological patients with neutropenic fever.

Leukemia & lymphoma·2026

Prognostic factors and survival in HHV8 positive diffuse large B cell lymphoma: a national cancer database analysis.

Leukemia & lymphoma·2026

A Novel BORCS5 Loss-Of-Function Variant in a Patient With a Rare Neurodevelopmental Disorder.

International journal of developmental neuroscience : the official journal of the International Society for Developmental Neuroscience·2026

Treatment Patterns and Survival Outcomes of Head and Neck Merkel Cell Carcinoma: An Age-Stratified Analysis.

Head & neck·2026
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies
Jove
Visualize
Contact Us